Aperio Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Aperio Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$410K	Buy	89,637 +7,697	+9%	+$34.1K	﹤0.01%	2054
2020 Q3	$318K	Sell	81,940 -3,485	-4%	-$14.9K	﹤0.01%	2051
2020 Q2	$407K	Sell	85,425 -1,087	-1%	-$4.48K	﹤0.01%	1872
2020 Q1	$301K	Buy	86,512 +56,569	+189%	+$240K	﹤0.01%	1899
2019 Q4	$144K	Buy	29,943 +5,527	+23%	+$19.2K	﹤0.01%	2242
2019 Q3	$71K	Buy	24,416 +12,083	+98%	+$42.2K	﹤0.01%	2264
2019 Q2	$88K	Sell	12,333 -7,330	-37%	-$74.9K	﹤0.01%	2417
2019 Q1	$279K	Sell	19,663 -15,648	-44%	-$207K	﹤0.01%	2031
2018 Q4	$478K	Sell	35,311 -5,964	-14%	-$107K	﹤0.01%	1702
2018 Q3	$916K	Sell	41,275 -1,967	-5%	-$41.4K	﹤0.01%	1462
2018 Q2	$709K	Buy	+43,242	New	+$759K	﹤0.01%	1569

Other funds holding AMRX

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Aperio Group's AMRX Position: Q4 2020 in Review

Aperio Group increased its Amneal Pharmaceuticals (AMRX) stake by 9.4% in Q4 2020, buying an estimated $34.1K and bringing the position to 89,637 shares worth $410K. The position accounts for ﹤0.01% of the portfolio, ranked #2054.

Aperio Group first reported a position in AMRX in Q2 2018 and has held it in 11 quarters since. The position peaked at $916K in Q3 2018. 133 funds tracked by Wall St. Rank hold AMRX as of Q4 2020.

Aperio Group held 89,637 shares of Amneal Pharmaceuticals worth $410K as of Q4 2020.
Aperio Group bought 7,697 Amneal Pharmaceuticals shares in Q4 2020, an estimated $34.1K.
Amneal Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2054 holding.
Aperio Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 11 quarters since.
Aperio Group's Amneal Pharmaceuticals position peaked at $916K in Q3 2018.
133 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.